600 related articles for article (PubMed ID: 33525562)
21. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition.
Liu X; Verma A; Garcia G; Ramage H; Lucas A; Myers RL; Michaelson JJ; Coryell W; Kumar A; Charney AW; Kazanietz MG; Rader DJ; Ritchie MD; Berrettini WH; Schultz DC; Cherry S; Damoiseaux R; Arumugaswami V; Klein PS
Proc Natl Acad Sci U S A; 2021 Oct; 118(42):. PubMed ID: 34593624
[TBL] [Abstract][Full Text] [Related]
22. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
Gould TD; Zarate CA; Manji HK
J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
[TBL] [Abstract][Full Text] [Related]
23. Lithium specificity in bipolar illness: a classic agent for the classic disorder.
Gershon S; Chengappa KN; Malhi GS
Bipolar Disord; 2009 Jun; 11 Suppl 2():34-44. PubMed ID: 19538684
[TBL] [Abstract][Full Text] [Related]
24. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
25. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders.
Bauer M; Alda M; Priller J; Young LT;
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S250-4. PubMed ID: 14677087
[TBL] [Abstract][Full Text] [Related]
26. Bipolar disorder.
Belmaker RH
N Engl J Med; 2004 Jul; 351(5):476-86. PubMed ID: 15282355
[No Abstract] [Full Text] [Related]
27. The impact of lithium on bipolar disorder.
Malhi GS
Bipolar Disord; 2009 Jun; 11 Suppl 2():1-3. PubMed ID: 19538680
[No Abstract] [Full Text] [Related]
28. Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response: Association With IMPA2, INPP1, and GSK3B Genes.
Mitjans M; Arias B; Jiménez E; Goikolea JM; Sáiz PA; García-Portilla MP; Burón P; Bobes J; Vieta E; Benabarre A
J Clin Psychopharmacol; 2015 Oct; 35(5):600-4. PubMed ID: 26267417
[TBL] [Abstract][Full Text] [Related]
29. Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder.
Atack JR; Broughton HB; Pollack SJ
Trends Neurosci; 1995 Aug; 18(8):343-9. PubMed ID: 7482796
[TBL] [Abstract][Full Text] [Related]
30. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.
Harwood AJ
Mol Psychiatry; 2005 Jan; 10(1):117-26. PubMed ID: 15558078
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms.
Serretti A; Drago A
Neuropsychobiology; 2010; 62(1):61-71. PubMed ID: 20453536
[TBL] [Abstract][Full Text] [Related]
32. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
Valvassori SS; Dal-Pont GC; Resende WR; Jornada LK; Peterle BR; Machado AG; Farias HR; de Souza CT; Carvalho AF; Quevedo J
Neuropharmacology; 2017 May; 117():447-459. PubMed ID: 27789311
[TBL] [Abstract][Full Text] [Related]
33. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.
Rowe MK; Wiest C; Chuang DM
Neurosci Biobehav Rev; 2007; 31(6):920-31. PubMed ID: 17499358
[TBL] [Abstract][Full Text] [Related]
34. Lithium Pharmacology and a Potential Role of Lithium on Methamphetamine Abuse and Dependence.
Kitanaka N; Hall FS; Uhl GR; Kitanaka J
Curr Drug Res Rev; 2019; 11(2):85-91. PubMed ID: 31875781
[TBL] [Abstract][Full Text] [Related]
35. Structural variation in the glycogen synthase kinase 3β and brain-derived neurotrophic factor genes in Japanese patients with bipolar disorders.
Suga Y; Yoshimoto K; Numata S; Shimodera S; Takamura S; Kamimura N; Sawada K; Kazui H; Ohmori T; Morinobu S
Neuropsychopharmacol Rep; 2020 Mar; 40(1):46-51. PubMed ID: 31769621
[TBL] [Abstract][Full Text] [Related]
36. Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy.
Damri O; Shemesh N; Agam G
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375448
[TBL] [Abstract][Full Text] [Related]
37. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.
Alda M
Mol Psychiatry; 2015 Jun; 20(6):661-70. PubMed ID: 25687772
[TBL] [Abstract][Full Text] [Related]
38. The new lithium clinic.
Osher Y; Bersudsky Y; Belmaker RH
Neuropsychobiology; 2010; 62(1):17-26. PubMed ID: 20453531
[TBL] [Abstract][Full Text] [Related]
39. Molecular Signatures of Lithium Treatment: Current Knowledge.
Bellivier F; Marie-Claire C
Pharmacopsychiatry; 2018 Sep; 51(5):212-219. PubMed ID: 30060262
[TBL] [Abstract][Full Text] [Related]
40. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.
Machado-Vieira R; Manji HK; Zarate CA
Bipolar Disord; 2009 Jun; 11 Suppl 2(Suppl 2):92-109. PubMed ID: 19538689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
